Technetium tc-99m tilmanocept - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for technetium tc-99m tilmanocept and what is the scope of patent protection?
Technetium tc-99m tilmanocept
is the generic ingredient in one branded drug marketed by Cardinal Health 414 and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.Technetium tc-99m tilmanocept has thirty patent family members in twelve countries.
One supplier is listed for this compound.
Summary for technetium tc-99m tilmanocept
International Patents: | 30 |
US Patents: | 2 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 7 |
DailyMed Link: | technetium tc-99m tilmanocept at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for technetium tc-99m tilmanocept
Generic Entry Date for technetium tc-99m tilmanocept*:
Constraining patent/regulatory exclusivity:
Dosage:
INJECTABLE;INJECTION |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for technetium tc-99m tilmanocept
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
John O. Prior | Early Phase 1 |
Eben Rosenthal | Phase 2 |
National Cancer Institute (NCI) | Phase 2 |
US Patents and Regulatory Information for technetium tc-99m tilmanocept
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cardinal Health 414 | LYMPHOSEEK KIT | technetium tc-99m tilmanocept | INJECTABLE;INJECTION | 202207-001 | Mar 13, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Cardinal Health 414 | LYMPHOSEEK KIT | technetium tc-99m tilmanocept | INJECTABLE;INJECTION | 202207-001 | Mar 13, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Cardinal Health 414 | LYMPHOSEEK KIT | technetium tc-99m tilmanocept | INJECTABLE;INJECTION | 202207-001 | Mar 13, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for technetium tc-99m tilmanocept
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Korea | 20110115148 | COMPOSITION FOR RADIOLABELING DIETHYLENETRIAMINEPENTAACETIC ACID(DTPF)-DEXTRAN | ⤷ Sign Up |
Canada | 2750230 | COMPOSITIONS DE RADIOMARQUAGE D'ACIDE DIETHYLENETRIAMINEPENTAACETIQUE (DTPA)-DEXTRAN (COMPOSITIONS FOR RADIOLABELING DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA)-DEXTRAN) | ⤷ Sign Up |
Brazil | PI1007487 | composição para radiomarcar ácido dietilenotriaminopentacético (dtpa)-dextrano | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for technetium tc-99m tilmanocept
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1178838 | 15C0033 | France | ⤷ Sign Up | PRODUCT NAME: TILMANOCEPT; REGISTRATION NO/DATE: EU/1/14/955 20141121 |
1178838 | 300736 | Netherlands | ⤷ Sign Up | PRODUCT NAME: TILMANOCEPT, DESGEWENST GELABELD MET TECHNETIUM TC 99M; REGISTRATION NO/DATE: EU/1/14/955 20141119 |
1178838 | 122015000033 | Germany | ⤷ Sign Up | PRODUCT NAME: TILMANOCEPT; REGISTRATION NO/DATE: C(2014) 8901 FINAL 20141119 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |